Skip to main content
. 2012 Nov 1;53(12):7432–7439. doi: 10.1167/iovs.12-9894

Figure 2.  .

Figure 2. 

ECM molecule protein levels as detected by ELISA in VIP-treated B6, PBS-treated B6, and PBS-treated BALB/c corneas under normal conditions and at 1 and 5 days after infection. ITG-α1 (A), CD44 (B), LAMA-1 (C), ECM1 (D), and VCAN (E) protein levels were significantly elevated in VIP-treated corneas over time when compared to PBS-treated B6 mice. In addition, VIP treatment showed similar trends to protein levels normally detected in PBS-treated BALB/c corneas after infection. SPP1 (F), in contrast, was significantly decreased (similar to PBS-treated BALB/c) after VIP treatment when compared to PBS B6 controls.

* ITG-α1: P = 0.01 (N), < 0.001 (day 1), = 0.004 (day 5); CD44: P = 0.007 (day 1), = 0.01 (day 5); LAMA-1: P < 0.001 (day 1, day 5); ECM1: P = 0.007 (day 5); VCAN: P = 0.01 (N), = 0.04 (day 1), = 0.002 (day 5); SPP1: P = 0.02 (N), < 0.001 (day 1, day 5) for VIP versus PBS B6.

# ITG-α1: P = 0.02 (N), < 0.001 (day 1), = 0.002 (day 5); CD44: P = 0.028 (day 5); ECM1: P = 0.02 (day 1), < 0.001 (day 5); VCAN: P = 0.002 (N), = 0.023 (day 1), < 0.001 (day 5); SPP1: P = 0.019 (N), < 0.001 (day 1, day 5) for PBS B6 versus PBS BALB/c.

& ITG-α1: P = 0.002 (day 1), = 0.008 (day 5); CD44: P = 0.004 (day 1); LAMA-1: P = 0.004 (day 1), < 0.001 (day 5); ECM1: P < 0.001 (day 5); VCAN: P = 0.002 (day 5); SPP1: P = 0.008 (day 5) for VIP versus PBS BALB/c.